Drug Trial Radar · NCT06795906
A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma
Last checked: Nov 19, 2026Latest source record: Oct 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jan 28, 2025
Primary completion
Jun 27, 2025
Study completion Jun 27, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jan 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomised, placebo-controlled, double-blinded, sponsor-unblinded study to assess the safety, pharmacokinetic (PK), and pharmacodynamic (PD) effect of AZD8630 in adult participants with asthma on medium-to-high dose inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA).
Conditions
- Asthma
Interventions
AZD8630Drug
AZD8630 will be administered via dry powder inhalation (DPI).
PlaceboOther
Placebo will be administered via DPI.
Saphira deviceDevice
AZD8630 or placebo will be administered to participants via Saphira device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse events (AEs) and serious adverse events (SAEs)Time frame: From Screening (Day -28) to Follow up (Day 21)
- Number of adverse events leading to discontinuation (DAEs)Time frame: From Day 1 to Day 14
- Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)Time frame: Day 1, Day 14 and Follow up (Day 21)
- Maximum observed plasma (peak) drug concentration (Cmax)Time frame: Day 1, Day 14 and Follow up (Day 21)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Ahrensburg, Germany
Research Site
Berlin, Germany
Research Site
Mainz, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.